Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

Pre-Marketing: $12 billion pharmacy deal

July 15, 2013: 6:50 AM ET


* Justin Fox: The upside of bad investment returns

* Can it last? The healthcare cost curve is flattening

* Daniel Gross: How Noodles & Co. punked Wall Street

* Big deal: Loblaw buying Shoppers Drug Mart for $12 billion

* Morning Call: U.S. futures point higher, Europe up and Japan climbs.

* A sound loss: RIP Amar Bose

* Sequestration: Pain in Pine Ridge

* Paul Graham: Do things that don't scale

* The 2.5X Rule: Must startups pay advisors?

* Fix student loan crisis? Put schools on the hook

* China's Q2 GDP: It slowed down, but not as much as feared

* Legal: Criminal charges against Solyndra founder unlikely

* Post Goldman, pre-trial: A global education for Fabrice Tourre

* Get Term Sheet: Sign up for our daily email on deals & dealmakers

*So long Codeacademy: MIT finds a way to program using natural language

* Barry Ritholtz: Rising rates mean golden window to fix infrastructure is closing

* Lawrence McDonald: Is Warren/McCain's Glass-Steagall revival a publicity stunt?

Posted in:
Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.